Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo

뉴스 본문을 불러오고 있어요.

Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo | 웨이프 WAPE

Ionis And AstraZeneca's CARDIO-TTRansform Phase 3 Trial Of Eplontersen Misses Primary Endpoint In Transthyretin-Mediated Amyloid Cardiomyopathy Patients Compared With Placebo

기사 요약

관련 종목

댓글 —